Mayne Pharma
Dr Carolyn Myers was appointed to the Board on 4 October 2021.
Dr Myers, a US resident, is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogen-repelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she was Vice President of Global Alliance Management and International Business Development at Allergan, Vice President of Marketing at Forest Laboratories, President of Dey Laboratories and President of Mylan Technologies. Dr Myers is a Steering Committee member of Mid Atlantic Bio Angels, a committee member of Golden Seeds and an independent board member of Hyloris Pharmaceuticals. She has a Ph.D. from the University of British Columbia and an M.B.A. from Rutgers University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Mayne Pharma
1 followers
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing branded and generic pharmaceuticals. It operates through four segments: Generic Products (GPD), Specialty Brands (SBD), Metrics Contract Services (MCS) and Mayne Pharma International (MPI). The GPD segment is engaged in the manufacture and distribution of generic pharmaceutical products in the United States. The SBD segment markets and distributes specialty branded pharmaceutical products in the United States. The MCS segment is engaged in the provision of contract analytical and pharmaceutical development services to third-party customers in the United States. The MPI segment is engaged in Australian manufacture and sale of branded and generic pharmaceutical product globally and provision of contract manufacturing services to third-party customers within Australia.